Crescent Biopharma
CBIO
89 hedge funds and large institutions have $145M invested in Crescent Biopharma in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
19% more capital invested
Capital invested by funds: $123M → $145M (+$22.7M)
11% more funds holding
Funds holding: 80 → 89 (+9)
0.03% less ownership
Funds ownership: 0.84% → 0.81% (-0.03%)
46% less call options, than puts
Call options by funds: $387K | Put options by funds: $714K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$8.06M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$3.15M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.85M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$1.75M |
| 5 |
Two Sigma Investments
New York
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.3M |
| 3 |
BlackRock
New York
|
-$1.12M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$1.05M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$896K |
CBIO Hedge Fund Activity: Q4 2020 in Review
89 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2020, worth a combined $145M — up 19% from $123M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CBIO positions and 13 closed out — a net gain of 9 holders — while 29 added to existing stakes and 22 trimmed.
The largest buyer was BVF Inc, adding an estimated $8.06M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.4M sold.
- 89 institutional investors held Crescent Biopharma (CBIO) as of Q4 2020, up from 80 in Q3 2020.
- Funds reported $145M of Crescent Biopharma stock for Q4 2020, up 19% quarter-over-quarter.
- 22 funds opened new Crescent Biopharma positions in Q4 2020 and 13 closed out, a net change of +9 holders.
- The largest Crescent Biopharma buyer in Q4 2020 was BVF Inc, an estimated $8.06M added.
- The largest Crescent Biopharma seller in Q4 2020 was EcoR1 Capital, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2020.